Leal Therapeutics

Leal Therapeutics

Private
Worcester, MassachusettsHealthcare & Life Scienceslealtx.com

Last Round

Series A

Aug 27, 2025

Total Funding Raised

$69M

Company Overview

Leal Therapeutics is a biotechnology company that develops innovative therapeutic solutions for major central nervous system conditions, providing patients with precision medicines to address urgent and unmet needs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Mental Health, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

antisense oligonucleotidesmall molecule therapeuticsASOCNS therapeuticsprecision medicineneurodegenerative diseasesneuropsychiatric diseasesALS therapyschizophrenia therapyneuro-metabolic therapiesmetabolic pathway targetingclinical-stage biotechdrug discoveryAlzheimer's disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Leal Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Leal Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AAug 27, 2025
VC RoundOct 30, 2024

Key People

Founding team and executive leadership

Asa Abeliovich

CEO And Founder

Founding Team

Xianglin Shi

Chief Technology Officer

Executive Team

Leal Therapeutics Investors

Notable investors and investment history

InvestorRounds
Newpath PartnersSeries A, VC Round
SV Health InvestorsSeries A
OrbiMedSeries A, VC Round, Seed
Chugai Venture FundSeries A, VC Round
Alexandria Venture InvestmentsSeries A, VC Round
PhiFund VenturesSeries A, Seed
Euclidean CapitalVC Round, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 13, 2026

    Raymond Jordt appointed as new Chief Business Officer.

  • Apr 13, 2026

    Johannes Tauscher, M.D. appointed as new CMO.

Leal Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Leal Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Leal Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWorcester, Massachusetts
Employee Range33
Year Founded2021
Last FundingAug 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.